TSHZ2 and ductal breast carcinoma in situ: Subsequent in vitro and in vivo experiments demonstrated that miR‐217 suppresses the malignancy and tumorigenesis of DCIS cells by regulating the DNMT1/TSHZ2/Hedgehog‐GLI signaling pathway, highlighting the potential of targeting this axis for novel therapeutic strategies against this disease.